8-K: Enliven Therapeutics Reports Strong Phase 1 Data for ELVN-001 in Heavily Pretreated CML Patients

Enliven Therapeutics, Inc. announced updated positive data from its Phase 1 ENABLE clinical trial for ELVN-001 in chronic myeloid leukemia (CML) patients, demonstrating favorable efficacy and safety profiles, particularly in heavily pretreated populations.

Summary

• Enliven Therapeutics announced updated positive data from its Phase 1 ENABLE clinical trial evaluating ELVN-001 in patients with chronic myeloid leukemia (CML).
• As of the cutoff date of April 28, 2025, 90 patients have been enrolled in the trial, with 80% remaining on study for a median duration of approximately 29 weeks.
• The patient population was heavily pretreated, with 67% having received three or more prior tyrosine kinase inhibitors (TKIs), including 58% with prior asciminib and 43% with prior ponatinib; 72% had discontinued their prior TKI due to lack of efficacy.
• Of 53 evaluable patients without T315I mutations, 47% (25 patients) achieved Major Molecular Response (MMR) by 24 weeks, with 32% (13 of 41) achieving and 100% (12 of 12) maintaining MMR.
• The achieved MMR rate of 32% compares favorably to historical data for asciminib (24% in Phase 1 and 25% in ASCEMBL Phase 3), despite ELVN-001 being studied in a more heavily pretreated population.
• ELVN-001 demonstrated a favorable safety and tolerability profile across all evaluated doses, with only 3.4% of patients experiencing dose reductions and 4.6% discontinuing due to treatment-emergent adverse events (TEAEs).
• The hematologic TEAE profile was similar to or better than approved TKIs, with no evidence of enhanced cardiovascular toxicity or treatment-related arterial occlusive events observed to date.
• The pharmacokinetic (PK) profile supports once-daily dosing with flexible administration (with or without food) and low potential for drug-drug interactions.
• The Company expects to initiate its first head-to-head Phase 3 pivotal trial for ELVN-001 in 2026.

Sentiment

Score: 9

Explanation: The document reports strong positive Phase 1 clinical trial data for ELVN-001, showing favorable efficacy and safety profiles that compare well against existing therapies in a challenging patient population. The company is confident enough to plan a pivotal Phase 3 trial in 2026, indicating significant progress and potential for the drug.

Positives

• High patient retention: 80% of patients remain on study with a median treatment duration of approximately 29 weeks.
• Strong efficacy in a challenging patient population: 47% cumulative Major Molecular Response (MMR) by 24 weeks (25 of 53 evaluable patients), with 32% (13 of 41) achieving MMR.
• Favorable comparison to existing therapies: Achieved MMR rate of 32% compares favorably to asciminib's historical rates of 24% (Phase 1) and 25% (ASCEMBL Phase 3), especially given the more heavily pretreated patient population.
• Excellent safety and tolerability: ELVN-001 is well-tolerated across all doses, with only 3.4% dose reductions and 4.6% discontinuations due to treatment-emergent adverse events (TEAEs).
• Low incidence of severe adverse events: Only 2.3% (2 of 87) of patients experienced Grade 3 non-hematologic treatment-related AEs.
• Favorable hematologic safety profile: Similar to or better than approved TKIs, with 6.9% (6 of 87) Grade 3 Thrombocytopenia and 5.7% (5 of 87) Grade 3 Neutropenia.
• No evidence of enhanced cardiovascular toxicity or arterial occlusive events (AOEs) observed to date.
• Maximum tolerated dose was not reached, and no exposure-toxicity relationship was observed, indicating a wide therapeutic window.
• Convenient pharmacokinetic profile: Supports once-daily dosing with or without food, and low potential for drug-drug interactions, which is beneficial for CML patients taking multiple concurrent medications.
• Company plans to initiate a head-to-head Phase 3 pivotal trial in 2026, indicating confidence in the drug's potential.

Risks

• The Company has a limited operating history.
• Ability to advance product candidates through preclinical and clinical development is uncertain.
• Obtaining regulatory approval for, and ultimately commercializing or licensing, product candidates, or identifying and completing strategic alternatives, is not guaranteed.
• The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and extrapolations or predictions regarding safety and efficacy based on comparisons to published results of other products may differ in head-to-head studies.
• The Company has limited resources.
• There is a risk of failing to demonstrate safety and efficacy of product candidates.
• The Company has limited experience in designing and conducting clinical trials.
• Interim, topline, and preliminary data from preclinical studies and clinical trials may materially change from the final data.
• Potential delays or difficulties in the enrollment or maintenance of patients in clinical trials.
• Developments relating to competitors and the industry, including competing product candidates and therapies, could impact the Company.
• The potential market opportunity for any of the Company's programs is uncertain.
• Decisions to develop or seek strategic collaborations for combination therapies and their associated costs pose risks.
• Ability to attract, hire, and retain highly skilled executive officers and employees is critical and uncertain.
• Ability to protect intellectual property and proprietary technologies, and the scope or loss of patent protection, are risks.
• Reliance on third parties, including medical institutions, contract manufacturing organizations, contract research organizations, and strategic partners, introduces dependencies.
• Geo-political developments, general market or macroeconomic conditions could adversely affect the Company.
• The Company's ability to obtain additional capital to fund general corporate activities and research and development is a risk.

Future Outlook

Enliven Therapeutics expects to initiate its first head-to-head Phase 3 pivotal trial for ELVN-001 in 2026. The company believes ELVN-001 has the potential to compete across all lines of therapy for CML, and that historical Phase 1 data in late-line CML trials have predicted success in subsequent pivotal trials, providing a roadmap for the regulatory pathway using biomarker-based endpoints like MMR for smaller, faster studies.

Management Comments

• "Thanks to the success of tyrosine kinase inhibitors (TKIs), patients with CML now have a near normal life expectancy. As a result, treatment goals have evolved beyond response and survival to also prioritize quality of life and tolerability. However, significant unmet needs remain, particularly related to treatment resistance and intolerance, across all lines of therapy. The data from ELVN-001 are encouraging, showing an efficacy, safety and tolerability profile that compare favorably to approved BCR::ABL1 inhibitors, despite being studied in a more heavily pretreated population. I look forward to future data, which could support ELVN-001 as a promising new option for patients who need better long-term disease management." Andreas Hochhaus, Professor of Internal Medicine, Hematology and Oncology and Head of the Department of Hematology and Medical Oncology at the Jena University Hospital, Germany.
• "We are highly encouraged by the ELVN-001 data, specifically as it relates to the consistency of the cumulative and achieved MMR rates as the Phase 1 trial progresses, with more evaluable patients and longer duration of treatment. While MMR is the efficacy endpoint in CML, safety and tolerability are equally critical given the chronic nature of the disease. ELVN-001 was reported to be well tolerated across all evaluated doses and had low levels of dose reductions and discontinuations, which we believe is the key sign of a favorable safety and tolerability profile. We believe ELVN-001 has the potential to offer best-in-class efficacy and tolerability, which are key attributes for people living with CML. We look forward to sharing additional data in the future." Helen Collins, M.D., Chief Medical Officer of Enliven.
• "We believe there remains significant opportunity to improve upon existing therapies. Based on todays encouraging Phase 1 update, we believe ELVN-001 has the potential to compete across all lines of therapy. We believe that precedent registrational trials in CML provide a roadmap for the regulatory pathway for ELVN-001, and the use of biomarker-based endpoints, like MMR, enables smaller, faster studies. Importantly, historical Phase 1 data in late-line CML trials have predicted success in subsequent pivotal trials. Building off this exciting update, we expect to initiate our first head-to-head Phase 3 pivotal trial in 2026 and remain confident in ELVN-001 and its potential positioning in the future in the CML treatment paradigm." Sam Kintz, Co-founder and Chief Executive Officer of Enliven.

Industry Context

The CML treatment landscape has significantly improved with the success of TKIs, leading to near-normal life expectancy. However, there remain significant unmet needs, particularly concerning treatment resistance and intolerance across all lines of therapy. ELVN-001 is positioned to address these gaps by offering a highly selective BCR::ABL1 inhibitor with a favorable efficacy and tolerability profile, potentially providing a new, promising option for heavily pretreated patients who have failed other TKIs like asciminib and ponatinib, and aiming to improve long-term disease management and quality of life.

Comparison to Industry Standards

• The achieved Major Molecular Response (MMR) rate by 24 weeks for ELVN-001 was 32% (13 of 41 patients).
• This compares favorably with historical data from less heavily pretreated patients receiving asciminib (Scemblix), which showed achieved MMR rates of 24% in its Phase 1 trial and 25% in the ASCEMBL Phase 3 trial.
• The hematologic treatment-emergent adverse event (TEAE) profile of ELVN-001 was reported to be similar to or better than that of approved TKIs.
• No evidence of enhanced cardiovascular toxicity or treatment-related arterial occlusive events has been observed to date with ELVN-001, which is a notable positive given the cardiovascular risks associated with some other TKIs.
• The company explicitly states that it has not performed any head-to-head trials for ELVN-001, and thus, conclusions from cross-trial comparisons with other products like asciminib cannot be definitively made due to differences in trial design and patient populations.

Stakeholder Impact

• Shareholders: The positive clinical data and clear progression towards a pivotal Phase 3 trial could significantly increase investor confidence and potentially lead to share price appreciation.
• Patients (CML): ELVN-001 offers a promising new treatment option, particularly for those who are heavily pretreated or resistant/intolerant to existing TKIs, potentially improving long-term disease management, quality of life, and tolerability.
• Employees: Positive trial results validate the company's research and development efforts and strategic direction, potentially boosting morale and job security.
• Healthcare Providers: The drug could provide an important new tool in managing CML, especially for challenging cases where current therapies are insufficient or poorly tolerated.

Next Steps

• Initiate the first head-to-head Phase 3 pivotal trial for ELVN-001 in 2026.
• Oral presentation of ENABLE trial data at the European Hematology Association (EHA) 2025 Congress on June 13, 2025.
• Host a webcast and conference call on June 13, 2025, at 1:30 p.m. ET / 7:30 p.m. CEST.
• Share additional data in the future.

Key Dates

Recommendation

Keywords

Enliven Therapeutics, ELVN-001, Chronic Myeloid Leukemia, CML, Phase 1 Clinical Trial, ENABLE trial, Tyrosine Kinase Inhibitor, TKI, BCR::ABL1, Major Molecular Response, MMR, Oncology, Biopharmaceutical, Clinical-stage, Drug development, Hematology, Adverse Events, Pharmacokinetics, Regulatory approval, Clinical data